Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan C Fox

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Future Cardiology|December 12, 2025
A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathyJulian D Gillmore, Daniel P Judge, Francesco Cappelli, et al.
Journal of Cardiac Failure|June 10, 2026
Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CMBrett W Sperry, Ahmad Masri, Kevin M Alexander, et al.
JAMA Cardiology|March 30, 2026
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialPrem Soman, Sarah A M Cuddy, Julian D Gillmore, et al.
Circulation|November 18, 2024
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM TrialDaniel P Judge, Julian D Gillmore, Kevin M Alexander, et al.
American Journal of Human Genetics|July 15, 2025
A calcium-sensing receptor allelic series and underdiagnosis of genetically driven hypocalcemiaJeremy B Chang, Connor P Barnhill, Alexander M Apostolov, et al.
JAMA Cardiology|November 8, 2025
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label ExtensionKevin M Alexander, Margot K Davis, Olakunle Akinboboye, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Future Cardiology|December 12, 2025
A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathyJulian D Gillmore, Daniel P Judge, Francesco Cappelli, et al.
Journal of Cardiac Failure|June 10, 2026
Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CMBrett W Sperry, Ahmad Masri, Kevin M Alexander, et al.
JAMA Cardiology|March 30, 2026
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialPrem Soman, Sarah A M Cuddy, Julian D Gillmore, et al.
Circulation|November 18, 2024
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM TrialDaniel P Judge, Julian D Gillmore, Kevin M Alexander, et al.
American Journal of Human Genetics|July 15, 2025
A calcium-sensing receptor allelic series and underdiagnosis of genetically driven hypocalcemiaJeremy B Chang, Connor P Barnhill, Alexander M Apostolov, et al.
JAMA Cardiology|November 8, 2025
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label ExtensionKevin M Alexander, Margot K Davis, Olakunle Akinboboye, et al.
Pageof 4